

Innovation all for the patients



Roche A member of the Roche group

Roche Announces New Two-Year Data of Evrysdi for Children with Spinal Muscular Atrophy (SMA)

TOKYO, October 15, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on October 14, regarding two-year data from the RAINBOWFISH study of Evrysdi® (generic name: risdiplam) for pre-symptomatic spinal muscular atrophy (from birth to 6 weeks of age at first dose).

Please refer to the link below for details of the press release:

Majority of children with spinal muscular atrophy (SMA) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrate

<https://www.roche.com/media/releases/med-cor-2024-10-14>

###